Blood pressure trial meta-analysis audit trail:
Home
Welcome to the blood pressure trial meta-analysis audit trail mini-site. This mini-site relates to our May 2009 BMJ paper.

Figures 1-5

Please click any of the thumbnails or captions below to see the full-size version of each top-level figure. Readers are encouraged to follow the "user tips" link for advice on using the audit trail facility.

Top-level Figure 1
Figure 1: Relative risk estimates of coronary heart disease (CHD) events in single drug blood pressure difference trials of beta−blockers in people with a history of CHD, separately for trials in which participants had myocardial infarction (MI) on entry (with short follow−up) and had long−term CHD without a recent infarct, and in trials of beta blockers in other circumstances, and other drugs in any circumstances.

 

Top-level Figure 2
Figure 2: Relative risk estimates of CHD events and stroke for a decrease in blood pressure of 10mmHg systolic/5mmHg diastolic in blood pressure difference trials and in epidemiological cohort studies. (Five trials included participants with and without vascular disease, so the total number of trials is five less than the sum of the three categories.)

 

Top-level Figure 3
Figure 3: Relative risk estimates of CHD events and stroke in single drug blood pressure difference trials of the five main classes of blood pressure lowering drug (CHD events in trials of beta-blockers in people with a history of CHD are excluded). The 'all classes of drug' estimate includes five trials in which different treated participants took different drugs.

 

Top-level Figure 4
Figure 4 : Relative risk estimates of CHD events and stroke in the 46 drug comparison trials comparing each of the five classes of blood pressure lowering drug with any other class of drug. (CHD events in trials of beta-blockers in people with a history of CHD are excluded.)

 

Top-level Figure 5
Figure 5: Relative risk estimates of CHD events and stroke in blood pressure difference trials according to pre-treatment diastolic and systolic blood pressures (taken as the average in the placebo group over the course of the trial).The 'all trials' estimate includes additional trials in which pre-treatment blood pressure was not recorded.
 
Top
 
by Wolfson Institute Website Manager © Queen Mary, University of London 2011
Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Charterhouse Square, London EC1M 6BQ Tel: 020 7882 3850 Fax: 020 7882 6270